EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Verruconis gallopava : an isavuconazonium foe

Divisha Sharma, Scott R Curry iD, Courtney E Harris, Alexandra Mills, Rachel Burgoon, Drew W Charles iD

ASM Case Reports · 02.09.2025 · 1 (5)

DOI: 10.1128/asmcr.00081-25 ↗

Kurz gefasst

Fallbericht in der Zeitschrift ASM Case Reports, erschienen am 02.09.2025. Verfasst von Divisha Sharma und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Disease, Medical University of South Carolina, Charleston, South Carolina, USA. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 8 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Verruconis gallopava is a dematiaceous and environmental commensal that rarely causes infection in humans. Human infections are typically observed in immunocompromised individuals. Clinical presentations range from localized infectious (skin and lung) to disseminated disease with a predilection for the central nervous system. Currently, no standardized guidelines exist for the treatment of V. gallopava . Most mold-active triazoles, except isavuconazole, have demonstrated in vitro antifungal activity against this pathogen. Case Summary We present a case of an immunocompromised male who underwent heart transplantation with subsequent syndrome of chronic pneumonia. Imaging suggested an atypical pulmonary process prompting empiric initiation of isavuconazonium. Despite treatment, the patient’s condition worsened, and fungal culture from sputum and bronchoalveolar lavage both grew V. gallopava . His symptoms persisted, and he was transitioned to liposomal amphotericin B and eventually oral posaconazole (POS) with clinical and radiographic resolution of his presenting syndrome.

Conclusion

This case highlights the limited experience and clinical failure of isavuconazonium as empiric therapy for V. gallopava . Transitioning to POS led to clinical improvement, suggesting its potential as a treatment option. Further experience is needed to establish optimal therapeutic strategies for this rare but serious infection.

Schlagwörter

Stichwörter der Autor:innen

Verruconis gallopavaisavuconazolepneumoniatransplant

Autor:innen und Institutionen

  • Division of Infectious Disease, Medical University of South Carolina, Charleston, South Carolina, USA.
  • Department of Pharmacy, Medical University of South Carolina, Charleston, South Carolina, USA.

ORCID-Profile: Scott R Curry, Drew W Charles

Zitieren

APA

Sharma, D., Curry, S. R., Harris, C. E., Mills, A., Burgoon, R., & Charles, D. W. (2025). Verruconis gallopava : an isavuconazonium foe. ASM Case Reports, 1(5). https://doi.org/10.1128/asmcr.00081-25

Vancouver

Sharma D, Curry SR, Harris CE, Mills A, Burgoon R, Charles DW. Verruconis gallopava : an isavuconazonium foe. ASM Case Reports. 2025;1(5). doi:10.1128/asmcr.00081-25

BibTeX
@article{Sharma2025,
  author = {Sharma, Divisha and Curry, Scott R and Harris, Courtney E and Mills, Alexandra and Burgoon, Rachel and Charles, Drew W},
  title = {Verruconis gallopava : an isavuconazonium foe},
  journal = {ASM Case Reports},
  year = {2025},
  volume = {1},
  number = {5},
  doi = {10.1128/asmcr.00081-25}
}
Kostenlos starten →